Finorga makes a significant investment in MCC technology

Published: 1-Jan-2003


To take advantage of the forecast 13% per annum growth in the global market for chiral pharmaceuticals, Finorga is investing €23m (US$23.2m) in Multi Column Chromatography (MCC) technology for the separation of chiral molecules. Finorga, a custom manufacturer of advanced intermediates and APIs, is part of Dynamic Synthesis, the custom synthesis division of Dynamit Nobel, of Germany. It has two cGMP sites in France, at Chasse-sur-Rhone and at Mourenx.

In August a new dedicated MCC facility came on stream at Chasse-sur-Rhone, while at Mourenx a production plant is currently under construction and will begin production this summer. At Finorga, MCC was developed and approved for the production of an intermediate of a pharmaceutical registered for the global market. This pharmaceutical is manufactured in both plants in the racemic form. The use of MCC has made the enantiomer available with increased drug efficiency and reduced side-effects, thereby opening doors for the marketing of the drug.

MCC investment is part of Dynamic Synthesis's long-term strategy to become a world-wide leader in separation technologies at the Finorga site. Once both projects are complete, Dynamic Synthesis will be able to undertake separation from r&d to pilot to industrial scale. The new pilot plant at Chasse-sur-Rhone has 200mm columns, while the new plant at Mourenx will have 600mm columns and be capable of an output of some 100kg/day of the desired enantiomer. Finorga will continue to operate its Licosep Lab to bridge between the r&d stage and pilot scale products and optimise process parameters.

At the beginning of December 2002 Finorga held a workshop, Chirality and Chromatography, that brought together experts from industry and university to discuss the prospects of MCC. Alfred Schulte, ceo of Dynamic Synthesis commented: 'In launching the MCC production facility, we offer our know-how in the separation of chiral molecules to the pharmaceutical industry - a technology now available for lab-scale up to production-scale synthesis.'

See more

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

Read more
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Subscribe now